Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 6/20 | 0.47 |
| ▸ | MET | P08581 | 6/20 | 0.47 |
| ▸ | TEK | Q02763 | 6/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.47 |
| ▸ | LCK | P06239 | 4/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308606 | 0.87 | CDC25B (0.46) | KDRPPARGNR4A1NR4A2NR4A3 | |
| SCHEMBL22048761 | 0.86 | KDR (0.55) | KDRAURKAMETTEKAURKB | |
| SCHEMBL22048385 | 0.85 | KDR (0.67) | KDRAURKAMETTEKAURKB | |
| SCHEMBL2706583 | 0.85 | KDR (0.50) | KDRPTPN1AURKAMETTEK | |
| SCHEMBL2708541 | 0.85 | KDR (0.49) | KDRPTPN1AURKAMETTEK | |
| SCHEMBL2747559 | 0.84 | KDR (0.63) | KDRPTPN1AURKAMETTEK | |
| SCHEMBL272878 | 0.84 | KDR (0.55) | KDRPTPN1AURKAMETTEK | |
| SCHEMBL272837 | 0.84 | KDR (0.56) | KDRPTPN1FLT1FLT4 | |
| SCHEMBL2747173 | 0.82 | KDR (0.53) | KDRPTPN1AURKAMETTEK | |
| SCHEMBL2747777 | 0.81 | KDR (0.69) | KDRAURKAMETTEKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-12-05 | — | — | US | disclosed |
| EP-3418277-B1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-10-14 | — | — | EP | disclosed |
| US-20200172510-A1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-04 | — | — | US | disclosed |
| US-8217045-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | disclosed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885PTPN1 1560/4885AURKA 4148/4885 |
| US-20100113467-A1 | Organic Compounds | SLCO2A1, SLCO1B1, SLCO2B1 | KDR 4081/4885PTPN1 3636/4885AURKA 312/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885PTPN1 1560/4885AURKA 4148/4885 |
| US-20200172510-A1 | SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCLIC RING COMPOUND AND PREPARATION AND USE THEREOF | NOS2, NOS1, NOS3 | KDR 157/4885PTPN1 334/4885AURKA 790/4885 |
| US-11834432-B2 | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | NOS2, NOS1, NOS3 | KDR 146/4885PTPN1 374/4885AURKA 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.